At the end of August 2024, the Bioprojet Laboratory informed the ANSM (National Agency for Drug Safety and Health Products) of a supply of supply of AUPEN adrenaline self-injectors. The 3 dosages (150 μg, 300 μg and 500 μg) were affected. In a communiqué Published on July 25, 2025, the laboratory reported to the ANSM that the situation had returned to normal for the AUPEN 150 and 300 μg auto-injectors, which are therefore available in city pharmacies.
Anapen 500 μg is still out of stock. Its provision should return to normal during 2026. In the meantime, the ANSM recommends that doctors prescribe to patients who used Anapen 500 μg to replace it with 1 or 2 pens of 300 μg of Anapen, Epipen or Jext, depending on the clinical situation.
For the record, the agency indicates that the stock breaking of Anapen 500 μg ” is not due to a quality defect. The laboratory explains it by a production of production site which led to a delay in supplies of the Anapen pens. Patients who currently have an anapen pen can use it until its expiration date ».
In the event of a prescription from another injector than Anapen (Epipen or Jext, which are not out of stock), the doctor will have to train his patient in his use.
